Thai Ba Trieu

Array ( [id] => 17355372 [patent_doc_number] => 20220016168 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => METHODS OF USING CD27 ANTIBODIES AS CONDITIONING TREATMENT FOR ADOPTIVE CELL THERAPY [patent_app_type] => utility [patent_app_number] => 17/298071 [patent_app_country] => US [patent_app_date] => 2019-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17298071 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15678551 [patent_doc_number] => 20200093939 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTICS [patent_app_type] => utility [patent_app_number] => 16/706065 [patent_app_country] => US [patent_app_date] => 2019-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 88697 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16706065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17368290 [patent_doc_number] => 20220023342 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => ANTI-NEUROPILIN-1 AND ANTI-PROGRAMMED CELL DEATH-1 COMBINATION THERAPY FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/297052 [patent_app_country] => US [patent_app_date] => 2019-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20797 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17297052 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17546673 [patent_doc_number] => 20220118014 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => PLACENTA-DERIVED ALLOGENEIC CAR-T CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/309451 [patent_app_country] => US [patent_app_date] => 2019-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8525 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17309451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17383897 [patent_doc_number] => 20220031749 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => MULTIPLEX GENOME EDITING OF IMMUNE CELLS TO ENHANCE FUNCTIONALITY AND RESISTANCE TO SUPPRESSIVE ENVIRONMENT [patent_app_type] => utility [patent_app_number] => 17/309408 [patent_app_country] => US [patent_app_date] => 2019-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30665 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -143 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17309408 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034441 [patent_doc_number] => 20240084256 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => METHOD FOR CULTURING CORD BLOOD-DERIVED NATURAL KILLER CELLS USING TRANSFORMED T-CELLS [patent_app_type] => utility [patent_app_number] => 17/293835 [patent_app_country] => US [patent_app_date] => 2019-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11635 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17293835 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17458736 [patent_doc_number] => 20220072040 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => TREATMENT METHOD FOR GRAFT-VERSUS-HOST DISEASE [patent_app_type] => utility [patent_app_number] => 17/314997 [patent_app_country] => US [patent_app_date] => 2019-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4430 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17314997 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156158 [patent_doc_number] => 20210317209 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => ANTI-CD79B ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/309144 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19850 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -119 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17309144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17894623 [patent_doc_number] => 20220304285 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => COMPOSITIONS AND METHODS FOR MULTIPLEXED QUANTITATIVE ANALYSIS OF CELL LINEAGES [patent_app_type] => utility [patent_app_number] => 17/281919 [patent_app_country] => US [patent_app_date] => 2019-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52327 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17281919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17241963 [patent_doc_number] => 20210361706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => COMBINATION OF NATURAL KILLER CELLS WITH CYCLOPHOSPHAMIDE COMPOUNDS FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/269612 [patent_app_country] => US [patent_app_date] => 2019-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9743 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17269612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17200106 [patent_doc_number] => 20210340201 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => IMMUNOTHERAPY TARGETING KRAS OR HER2 ANTIGENS [patent_app_type] => utility [patent_app_number] => 17/270400 [patent_app_country] => US [patent_app_date] => 2019-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40777 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17270400 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17050703 [patent_doc_number] => 20210260137 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => MITOCHONDRIAL AUGMENTATION THERAPY FOR PRIMARY MITOCHONDRIAL DISEASES [patent_app_type] => utility [patent_app_number] => 17/253455 [patent_app_country] => US [patent_app_date] => 2019-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22937 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17253455 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17342151 [patent_doc_number] => 20220008482 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2022-01-13 [patent_title] => Reprogramming Cells With Synthetic Messenger RNA [patent_app_type] => utility [patent_app_number] => 16/974280 [patent_app_country] => US [patent_app_date] => 2019-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13072 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16974280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17342151 [patent_doc_number] => 20220008482 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2022-01-13 [patent_title] => Reprogramming Cells With Synthetic Messenger RNA [patent_app_type] => utility [patent_app_number] => 16/974280 [patent_app_country] => US [patent_app_date] => 2019-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13072 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16974280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17035233 [patent_doc_number] => 20210252191 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => INJECTABLE AMNION HYDROGEL AS A CELL DELIVERY SYSTEM [patent_app_type] => utility [patent_app_number] => 16/973198 [patent_app_country] => US [patent_app_date] => 2019-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11349 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16973198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17005386 [patent_doc_number] => 20210236547 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => RAPID PRODUCTION, EXPANSION, AND INCREASED PURITY OF CAR-T CELLS USING BEADS WITH PROTEIN L [patent_app_type] => utility [patent_app_number] => 16/972223 [patent_app_country] => US [patent_app_date] => 2019-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3599 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16972223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16948406 [patent_doc_number] => 20210207097 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => EXPANSION AND CULTURE OF HUMAN-DERIVED NATURAL KILLER CELLS BY USING IGFBP2 [patent_app_type] => utility [patent_app_number] => 17/059509 [patent_app_country] => US [patent_app_date] => 2019-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2769 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17059509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16778300 [patent_doc_number] => 20210115378 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => COMPOSITIONS AND SYSTEMS FOR EX VIVO CELL MODULATION AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/054115 [patent_app_country] => US [patent_app_date] => 2019-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27018 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17054115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16627466 [patent_doc_number] => 20210046119 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => FIXED RATIO EX VIVO ACTIVATED MIXED LYMPHOCYTE PRODUCTS FOR USE IN THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/049307 [patent_app_country] => US [patent_app_date] => 2019-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30332 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17049307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16886704 [patent_doc_number] => 20210172900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => METHOD FOR MONITORING THE VIABILITY OF A GRAFT [patent_app_type] => utility [patent_app_number] => 17/047945 [patent_app_country] => US [patent_app_date] => 2019-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5538 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17047945 [rel_patent_id] =>[rel_patent_doc_number] =>)